GX BIO LABS · Product artwork
Ipamorelin is a synthetic peptide studied as a growth hormone secretagogue and ghrelin-receptor agonist. Its literature includes animal pharmacology and a human trial of postoperative bowel function, with distinct endpoints and limitations.
10 available
Check COA availabilityCOA not yet available for this strength
Not for human or veterinary administration. Listed strength is a supplied specification; see the matching batch report for measured results.
Early ipamorelin research examined growth hormone release in cultured rat pituitary cells and animal models, including comparisons with other secretagogues. A later human proof-of-concept trial investigated postoperative ileus in patients undergoing bowel resection. That trial assessed tolerance of a standardised meal and other bowel-recovery outcomes, rather than muscle growth, exercise performance or ageing. The preclinical and clinical studies therefore answer different questions. Receptor activity and hormone measurements should be read as experimental findings, while the surgical trial provides a limited test in a specific patient group. Neither establishes the characteristics of this research vial.
Each source identifies what was studied and the limits of its findings. Published research is separate from this product’s batch COA.
Researchers examined growth hormone release in rat pituitary cells, rats and swine. Hormone-response and selectivity findings describe those experimental systems and are not evidence of clinical benefit.
Read studyThis randomised, placebo-controlled study investigated postoperative ileus after bowel resection. It found no significant differences in its key or secondary efficacy analyses; the study was small and included patients with varied underlying conditions.
Read studyIpamorelin is currently listed in 5 mg, 10 mg. Select a strength above to see its price, product image and current stock. Listed quantities are supplied specifications, not measured batch results.
No laboratory report is currently published for this compound. Request the available documentation before relying on any batch-specific measurement. A scientific paper is not a substitute for a COA.
A catalogue listing is not a laboratory measurement. Check original documentation for the selected strength and batch before relying on identity, purity or quantity information.
Tesamorelin is a growth hormone-releasing hormone analogue studied in defined clinical populations, particularly people with HIV-associated abdominal fat accumulation. Published findings concern the study formulations and do not establish the properties of this research vial.
This listing is CJC-1295 No DAC. The linked human study concerns the related, long-acting albumin-binding CJC-1295 compound and is provided as context, not direct evidence for the no-DAC material.
HGH denotes human growth hormone. Clinical research on recombinant growth hormone formulations, including somatropin, provides endocrine context but does not validate the identity, potency or clinical suitability of a research vial.